SARS-CoV-2 spike protein licensed by Oragenics from the NIH demonstrated protective immunity in mice
On Feb. 2, 2021, Oragenics announced that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National…
On Feb. 2, 2021, Oragenics announced that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National…
On Feb. 2, 2021, VBI Vaccines announced that the FDA had accepted its filing of the Biologics License…
On Feb. 2, 2021, Novavax announced a memorandum of understanding (MOU) with the Canadian government to produce NVX-CoV2373,…
On Feb. 1, 2021, Roche announced it had obtained the CE mark for its new SARS-CoV-2 Rapid Antigen…
On Feb. 1, 2021, researchers at the National Institutes of Health and their collaborators found that inhaling unfragmented…
On Feb. 1, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced a plan to initiate a global Phase 2/3…
On Feb. 1, 2021, Dynavax Technologies and the Coalition for Epidemic Preparedness Innovations (CEPI) announced they have entered…
On Feb. 1, 2021, Dynavax Technologies announced Valneva had informed it that the UK Government exercised its option…
On Feb. 1, 2021, Pfizer and BioNTech announced that preclinical data in non-human primate and mouse models from…
On Jan. 31, 2021, Sorrento Therapeutics announced additional positive results from its Phase 1b study of human allogeneic…
On Jan. 30, 2021, as the COVID-19 pandemic continued to surge in the U.S., the CDC implemented a…
On Jan. 29, 2021, Rigel Pharma announced it has been awarded $16.5 million by the U.S. Department of…
On Jan. 29, 2021, Humanigen announced it had completed enrollment for its pivotal phase 3 study of lenzilumab…
On Jan. 29, 2021, Innovation Pharmaceuticals announced that the companyメs Phase 2 clinical trial of Brilacidin for treating…
On Jan. 29, 2021, Johnson & Johnson announced topline efficacy and safety data from the Phase 3 ENSEMBLE…
On Jan. 29, 2021, Pfizer and BioNTech announced that data from an in vitro study on the capability…
On Jan. 29, 2021, OraSure Technologies announced its OMNIgene®·ORAL (OM-505) saliva collection kit, a product of subsidiary DNA…
On Jan. 28, 2021, National Institutes of Health (NIH) researchers reported that pregnant women who experienced severe symptoms…
On Jan. 28, 2021, scientists at the National Eye Institute (NEI) have developed a promising gene therapy strategy…
On Jan. 28, 2021, The WHO announced that COVID-19 cases and deaths were surging in Africa as more…
On Jan. 28, 2021, the CDC announced that it had become aware of the first U.S. documented cases…
On Jan 28, 2021, Mammoth Biosciences announced a co-marketing agreement with Agilent Technologies to support the anticipated launch…
On Jan. 28, 2021, Precipio announced that following receipt of an Emergency Use Authorization from the U.S. Food…
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
On Jan. 28, 2021, Celsion announced the filing of a provisional U.S. patent application for a novel DNA-based,…
On Jan. 28, 2021, OraSure Technologies announced its OMNIgene®·ORAL (OME-505) saliva collection device, a product of Ottawa-based subsidiary…
On Jan. 27, 2021, researchers at the Broad Institute of MIT and Harvard, and Massachusetts General Hospital’s Center…
On Jan. 27, 2021, Heat Biologics announced the publication of additional preclinical COVID-19 results in Frontiers in Immunology,…
On Jan. 27, 2021, researchers in Dr. David Ho’s Columbia University lab and Regeneron scientists announced they had…
On Jan. 27, 2021, Pfizer and BioNTech announced results from in vitro neutralization studies of sera from individuals…